S

SWK Holdings Corp
NASDAQ:SWKH

Watchlist Manager
SWK Holdings Corp
NASDAQ:SWKH
Watchlist
Price: 17.29 USD 0.88% Market Closed
Market Cap: 209.2m USD

SWK Holdings Corp
Other Current Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

SWK Holdings Corp
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
S
SWK Holdings Corp
NASDAQ:SWKH
Other Current Liabilities
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
LM Funding America Inc
NASDAQ:LMFA
Other Current Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A-Mark Precious Metals Inc
NASDAQ:AMRK
Other Current Liabilities
$993.5m
CAGR 3-Years
52%
CAGR 5-Years
37%
CAGR 10-Years
27%
California First Leasing Corp
OTC:CFNB
Other Current Liabilities
$45k
CAGR 3-Years
-32%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Standard Premium Finance Holdings Inc
OTC:SPFX
Other Current Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SUI Group Holdings Ltd
NASDAQ:SUIG
Other Current Liabilities
$12.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
105%
No Stocks Found

SWK Holdings Corp
Glance View

Market Cap
209.1m USD
Industry
Financial Services

SWK Holdings Corp. is engaged in the business of financial and asset management in the field of pharmaceutical. The company is headquartered in Dallas, Texas and currently employs 35 full-time employees. The firm is focused on providing various capital solutions to a range of life science companies, institutions and inventors. The firm operates through two segments: Finance Receivables and Pharmaceutical Development. Its Finance Receivables segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. In addition, through its wholly owned subsidiary, SWK Advisors LLC, it provides non-discretionary investment advisory services to institutional clients in separately managed accounts to similarly invest in life science finance. Through its subsidiary, Enteris BioPharma, Inc., its Pharmaceutical Development segment offers formulation solutions built around its oral drug delivery technology, the Peptelligence platform.

SWKH Intrinsic Value
24.72 USD
Undervaluation 30%
Intrinsic Value
Price
S

See Also

What is SWK Holdings Corp's Other Current Liabilities?
Other Current Liabilities
0 USD

Based on the financial report for Sep 30, 2025, SWK Holdings Corp's Other Current Liabilities amounts to 0 USD.

Back to Top